NASDAQ:AVLN Avalyn Pharma Q1 2026 Earnings Report $31.52 -1.91 (-5.71%) As of 09/18/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Avalyn Pharma EPS ResultsActual EPS-$21.83Consensus EPS -$16.38Beat/MissMissed by -$5.45One Year Ago EPSN/AAvalyn Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAvalyn Pharma Announcement DetailsQuarterQ1 2026Date6/3/2026TimeBefore Market OpensConference Call DateWednesday, June 3, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Avalyn Pharma Earnings HeadlinesAvalyn Pharma Adds Former FDA Executive To Board As AP01, AP02 Trials ProgressSeptember 17 at 9:00 AM | rttnews.comAvalyn Appoints Robert J. Meyer, MD, to its Board of DirectorsSeptember 16 at 4:01 PM | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 19 at 1:00 AM | Porter & Company (Ad)Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comAvalyn Pharma (NASDAQ:AVLN) Upgraded by Wall Street Zen to Hold RatingSeptember 12, 2026 | americanbankingnews.comAvalyn Pharma Inc. (NASDAQ:AVLN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 11, 2026 | americanbankingnews.comSee More Avalyn Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avalyn Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalyn Pharma and other key companies, straight to your email. Email Address About Avalyn PharmaAvalyn Pharma (NASDAQ:AVLN) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects. Avalyn’s lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function. The company has also pursued additional inhaled therapies for fibrotic lung conditions, although the status and scope of its development programs may change as clinical research progresses. Avalyn Pharma is headquartered in the United States and conducts its operations through the development of investigational medicines rather than through a commercial product portfolio. As a clinical-stage company, its programs remain subject to clinical testing and regulatory review before they can become broadly available to patients.View Avalyn Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
